Universität zu Köln

Cornely, Oliver A., Mullane, Kathleen M., Ostrosky-Zeichner, Luis, Maher, Rochelle M., Croos-Dabrera, Rodney, Lu, Qiaoyang, Lademacher, Christopher, Perfect, John R., Oren, Ilana, Schmitt-Hoffmann, Anne-Hortense, Giladi, Michael, Marty, Francisco M. ORCID: 0000-0002-3708-8734 and Rahav, Galia (2018). Isavuconazole for treatment of rare invasive fungal diseases. Mycoses, 61 (8). S. 518 - 534. HOBOKEN: WILEY. ISSN 1439-0507

Full text not available from this repository.

Abstract

Data regarding treatment of rare invasive fungal diseases (IFDs) are scarce. We documented the efficacy and safety of isavuconazole for treatment of uncommonly diagnosed IFDs. VITAL was a single-arm, international, open-label study evaluating the efficacy and safety of isavuconazole (200mg orally or intravenously every 8hours for 48hours, then once daily). The primary outcome was overall response at Day 42; key secondary outcomes were overall responses at Day 84 and end of treatment (EOT), mortality at Days 42 and 84, and safety. This analysis includes patients with IFD caused by rare or unidentified pathogens. Twenty-six patients with IFDs caused by rare moulds (n=17), non-Candida yeasts (n=2), or unidentified moulds (n=7) were enrolled (median treatment duration [range], 114.5 [1-496]) days. Overall treatment success was observed in 11/26 (42.3%), 10/26 (38.5%), and 15/26 (57.7%) patients at Days 42, 84, and EOT, respectively. All-cause mortality rates were 2/26 patients (7.7%) at Day 42 and 4/26 patients (15.4%) at Day 84; another two patients died after Day 84. All patients had 1 treatment-emergent adverse event (TEAE); 15 patients (57.7%) had serious TEAEs, and TEAEs led to discontinuation of isavuconazole in four patients (15.4%). Isavuconazole may be efficacious for treatment of a range of rare IFDs.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cornely, Oliver A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mullane, Kathleen M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ostrosky-Zeichner, Luis UNSPECIFIED UNSPECIFIED UNSPECIFIED Maher, Rochelle M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Croos-Dabrera, Rodney UNSPECIFIED UNSPECIFIED UNSPECIFIED Lu, Qiaoyang UNSPECIFIED UNSPECIFIED UNSPECIFIED Lademacher, Christopher UNSPECIFIED UNSPECIFIED UNSPECIFIED Perfect, John R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Oren, Ilana UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmitt-Hoffmann, Anne-Hortense UNSPECIFIED UNSPECIFIED UNSPECIFIED Giladi, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Marty, Francisco M. UNSPECIFIED orcid.org/0000-0002-3708-8734 UNSPECIFIED Rahav, Galia UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-177423
DOI:	10.1111/myc.12778
Journal or Publication Title:	Mycoses
Volume:	61
Number:	8
Page Range:	S. 518 - 534
Date:	2018
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1439-0507
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language IN-VITRO ACTIVITIES; 8 ANTIFUNGAL DRUGS; JOINT CLINICAL GUIDELINES; SUSCEPTIBILITY PROFILES; TRANSPLANT PATIENT; GLOBAL COLLECTION; FILAMENTOUS FUNGI; ESCMID-DAGGER; INFECTIONS; MANAGEMENT Multiple languages Dermatology; Mycology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/17742